Edition:
United Kingdom

Aptevo Therapeutics Inc (APVO.OQ)

APVO.OQ on NASDAQ Stock Exchange Global Select Market

5.67USD
18 May 2018
Change (% chg)

$-0.27 (-4.55%)
Prev Close
$5.94
Open
$5.95
Day's High
$6.07
Day's Low
$5.60
Volume
96,080
Avg. Vol
34,927
52-wk High
$6.30
52-wk Low
$1.18

Latest Key Developments (Source: Significant Developments)

Aptevo Therapeutics Announces Plans To Conduct Phase 2 Study Of Otlertuzumab In Peripheral T-Cell Lymphoma
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS ANNOUNCES PLANS TO CONDUCT PHASE 2 STUDY OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA.APTEVO THERAPEUTICS INC- ‍EXPECTS TO FILE 2 IND APPLICATIONS IN 2018 FOR 2 BISPECIFIC ANTIBODY CANDIDATES, APVO436 AND APVO210​.  Full Article

Aptevo Therapeutics files mixed shelf of up to $150 mln
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Aptevo Therapeutics Inc :Aptevo Therapeutics Inc files for mixed shelf of up to $150 million - SEC filing‍​.  Full Article

Aptevo Therapeutics reports third quarter 2017 financial results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Aptevo Therapeutics Inc :Aptevo Therapeutics reports third quarter 2017 financial results.Q3 earnings per share $1.77.  Full Article

BRIEF-Aptevo Therapeutics Q1 Loss Per Share $0.63

* APTEVO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS